Wendelin Schramm1. 1. GECKO Institute for Medicine, Informatics, and Economics, Heilbronn University, Heilbronn, Germany. wendelin.schramm@hs-heilbronn.de
Abstract
INTRODUCTION: In times of short health care budgets, reimbursement for self-monitoring of blood glucose (SMBG) in diabetes patients without insulin treatment is subject to debate. The Structured Testing Program (STeP) trial found a positive correlation of test frequency and improved hemoglobin A1c (HbA1c) levels in poorly controlled type 2 diabetes patients not treated with insulin. METHODS: A structured literature search for other clinical studies reporting on SMBG frequency was performed. RESULTS: There is scarce evidence: three trials, including STeP, noted a significant and relevant correlation between testing frequency and improved HbA1c levels (FA effect), whereas two studies did not. The comparability between the identified studies is problematic. CONCLUSION: Future research should consider correlations between testing frequency and level of glycemic control. More emphasis should be placed on a structured approach to use SMBG and to address adherence to testing and therapy.
INTRODUCTION: In times of short health care budgets, reimbursement for self-monitoring of blood glucose (SMBG) in diabetespatients without insulin treatment is subject to debate. The Structured Testing Program (STeP) trial found a positive correlation of test frequency and improved hemoglobin A1c (HbA1c) levels in poorly controlled type 2 diabetespatients not treated with insulin. METHODS: A structured literature search for other clinical studies reporting on SMBG frequency was performed. RESULTS: There is scarce evidence: three trials, including STeP, noted a significant and relevant correlation between testing frequency and improved HbA1c levels (FA effect), whereas two studies did not. The comparability between the identified studies is problematic. CONCLUSION: Future research should consider correlations between testing frequency and level of glycemic control. More emphasis should be placed on a structured approach to use SMBG and to address adherence to testing and therapy.
Authors: Andrew J Karter; Melissa M Parker; Howard H Moffet; Michele M Spence; James Chan; Susan L Ettner; Joe V Selby Journal: Diabetes Care Date: 2006-08 Impact factor: 19.112
Authors: M Schütt; W Kern; U Krause; P Busch; A Dapp; R Grziwotz; I Mayer; J Rosenbauer; C Wagner; A Zimmermann; W Kerner; R W Holl Journal: Exp Clin Endocrinol Diabetes Date: 2006-07 Impact factor: 2.949
Authors: William H Polonsky; Lawrence Fisher; Charles H Schikman; Deborah A Hinnen; Christopher G Parkin; Zhihong Jelsovsky; Bettina Petersen; Matthias Schweitzer; Robin S Wagner Journal: Diabetes Care Date: 2011-02 Impact factor: 19.112
Authors: Werner A Scherbaum; Christian Ohmann; Heinz-Harald Abholz; Nico Dragano; Mark Lankisch Journal: PLoS One Date: 2008-08-28 Impact factor: 3.240